Viking Global Investors LP Amends BridgeBio Pharma Stake

TL;DR

Viking Global Investors LP updated their BridgeBio Pharma stake filing. Keep an eye on this one.

AI Summary

Viking Global Investors LP, through its affiliates, has amended its Schedule 13D filing regarding BridgeBio Pharma, Inc. The filing, dated August 20, 2024, indicates a change in beneficial ownership. Viking Global Investors LP is a significant holder of BridgeBio Pharma, Inc. stock.

Why It Matters

This filing signals a potential shift in significant shareholder activity for BridgeBio Pharma, Inc., which could influence stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Changes in significant shareholder filings can indicate shifts in investment strategy or potential activism, impacting stock volatility.

Key Players & Entities

• Viking Global Investors LP (company) — Filing entity
• BridgeBio Pharma, Inc. (company) — Subject company
• DAVID C. OTT (person) — Group member
• O. ANDREAS HALVORSEN (person) — Group member
• ROSE S. SHABET (person) — Group member

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
• $300 million — s Complex. The Investors have committed $300 million of tranched financing to GondolaBio. Th

Filing Documents

• ef20034416_sc13da.htm (SC 13D/A) — 356KB
• 0001140361-24-037981.txt ( ) — 358KB

of the Schedule 13D is hereby amended and supplemented as follows

Item 4 of the Schedule 13D is hereby amended and supplemented as follows : On August 16, 2024, the Issuer, on the recommendation of a special committee of independent and disinterested directors of the Issuer, entered into a transaction agreement (the " Transaction Agreement ") providing for the formation and funding by certain third party investors (the " Investors ") of GondolaBio, LLC, a Delaware limited liability company (" GondolaBio "), as a joint venture for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including those contributed to GondolaBio by the Issuer (the " Transaction "). The Investors providing financing to GondolaBio consist of an investor syndicate, including Opportunities Fund and Viking Global Opportunities Drawdown (Aggregator) LP (" VGOD "). The general partner of VGOD is Viking Global Opportunities Drawdown Portfolio GP LLC, whose sole member is Viking Global Opportunities Drawdown GP LLC, whose sole member is Opportunities Parent. The Transaction was consummated (the " Closing ") on the date of signing the Transaction Agreement. Pursuant to the Transaction Agreement, the Issuer contributed to GondolaBio certain early-stage clinical and pre-clinical stage programs in the areas of Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. The Investors have committed $300 million of tranched financing to GondolaBio. The initial interest in GondolaBio of each of Opportunities Fund and VGOD is approximately 12% and 6%, respectively, and is expected to increase as additional tranches of capital contributions are funded. Also on August 16, 2024, each of the Investors, including Opportunities Fund and VGOD, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio (the " LLC Agreement "). The LLC Agreement sets forth, among other things, the economic and governance rights of the members of GondolaBio, including governance r

of the Schedule 13D is hereby amended and supplemented as follows

Item 6 of the Schedule 13D is hereby amended and supplemented as follows : The information set forth or included in Item 4 of this Amendment No. 3 is incorporated herein by reference. Item 7. Materials to be Filed as Exhibits

of the Schedule 13D is hereby amended and supplemented as follows

Item 7 of the Schedule 13D is hereby amended and supplemented as follows : Exhibit No. Description 99.4 Transaction Agreement, dated as of August 16, 2024, by and among the Issuer, the Investors and GondolaBio (incorporated by reference to Exhibit 10.1 to the Issuer's current report on Form 8-K dated August 20, 2024). 99.5 Amended and Restated Limited Liability Company Agreement of GondolaBio, dated as of August 16, 2024 (incorporated by reference to Exhibit 10.2 to the Issuer's current report on Form 8-K dated August 20, 2024). CUSIP No: 10806X102 SCHEDULE 13D Page 15 of 15

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: August 20, 2024 By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of O. Andreas Halvorsen (1) By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of David C. Ott (2) By: /s/ Scott M. Hendler Name: Scott M. Hendler on behalf of Rose S. Shabet (3) (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO

View Full Filing

View this SC 13D/A filing on SEC EDGAR